No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
ACET Adicet Bio
- 1.240
- +0.010+0.81%
Close Jul 19 16:00 ET
101.90MMarket Cap-421P/E (TTM)
1.260High1.160Low1.23MVolume1.260Open1.230Pre Close1.47MTurnover2.71%Turnover RatioLossP/E (Static)82.17MShares3.77052wk High0.39P/B56.11MFloat Cap1.05052wk Low--Dividend TTM45.25MShs Float214.348Historical High--Div YieldTTM8.13%Amplitude0.931Historical Low1.197Avg Price1Lot Size
Pre-Market
- 5D
- Daily
- Weekly
- Monthly
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Adicet Stock Jumps 10% on FDA Fast Track Status for ADI-270
Buy Rating Affirmed for Adicet Bio on Strong Therapy Pipeline and Positive Financial Projections
Express News | Adicet Bio Shares Are Trading Higher After the Company Announced That the FDA Granted It Fast Track Designation to ADI-270 for the Potential Treatment of Patients With Metastatic/advanced Clear Cell Renal Cell Carcinoma
Express News | The FDA Has Granted Fast Track Designation To Adicet Bio's ADI-270 For Metastatic/Advanced Clear Cell Renal Cell Carcinoma Patients Who Have Been Treated With An Immune Checkpoint Inhibitor And A Vascular Endothelial Growth Factor Inhibitor
Express News | Adicet Bio Receives FDA Fast Track Designation for Adi-270 in Metastatic/Advanced Clear Cell Renal Cell Carcinoma
Express News | HC Wainwright & Co. Reiterates Buy on Adicet Bio, Maintains $10 Price Target
Comments
$Adicet Bio(ACET.US$ The FDA Has Granted Fast Track Designation To Adicet Bio's ADI-270 For Metastatic/Advanced Clear Cell Renal Cell Carcinoma Patients Who Have Been Treated With An Immune Checkpoint Inhibitor And A Vascular Endothelial Growth Factor Inhibitor
1
$Adicet Bio(ACET.US$ Adicet Bio Highlights Preclinical Data Supporting Ind Readiness for Adi-270 in an Oral Presentation at the American Society of Gene and Cell Therapy (Asgct) 27TH Annual Meeting. Preclinical Findings Showed Robust Anti-Tumor Activity of Adi-270 in Multiple Cd70-Positive Solid and Hematological Cancer Models
$Adicet Bio(ACET.US$ Adicet Bio On Track to File IND for ADI-270 in Renal Cell Carcinoma in 2Q >ACET
Dow Jones· 5 mins ago
Dow Jones· 5 mins ago
$Adicet Bio(ACET.US$ Adicet Bio, Inc. Announces Closing of $98 Million Public Follow-On Offering and Exercise in Full of the Underwriters' Option to Purchase Additional Shares
7 MINUTES AGO, 4:01 PM EST
VIA BUSINESSWIRE![]()
7 MINUTES AGO, 4:01 PM EST
VIA BUSINESSWIRE
$Adicet Bio(ACET.US$
Analysts monitoring Adicet Bio come to a price target consensus of $14.75
Analysts monitoring Adicet Bio come to a price target consensus of $14.75
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg